Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2019-11-15 Interim / Quarterly Rep…
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - September 2019'. It contains detailed financial statements, including net sales, operating loss, loss per share, and cash flow data, as well as management commentary on clinical programs and market analysis. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2019
2019-11-15 English
Cantargia reports filing of opposition against Cantargia patent in Europe
Legal Proceedings Report Classification · 95% confidence The document is a press release dated October 10, 2019, announcing that an opposition has been filed against one of Cantargia's European patents (EP3020730B1) related to antibody therapy. It discusses ongoing legal/patent proceedings and includes a quote from the CEO. This type of announcement regarding significant legal or regulatory challenges, specifically patent opposition, fits best under the 'Legal Proceedings Report' category, as it details a specific legal matter involving the company's intellectual property. It is not a standard financial report (10-K, IR, ER) or a management change announcement. Given the focus on a patent dispute, LTR (Legal Proceedings Report) is the most appropriate classification.
2019-10-10 English
Cantargia meddelar att en opposition lämnats in mot ett av Cantargias patent i Europa
Legal Proceedings Report Classification · 95% confidence The document is a press release ("Pressmeddelande") from Cantargia AB dated October 10, 2019. The core content announces that an opposition has been filed against one of Cantargia's European patents (EP3020730B1) concerning antibody treatment for solid tumors. It details the legal/patent situation and includes a quote from the CEO. This type of announcement regarding legal proceedings, specifically patent challenges, fits best under the 'Legal Proceedings Report' (LTR) category, as it is a specific update on a significant legal/regulatory matter involving the company's intellectual property. It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), but a specific report on a legal/patent dispute.
2019-10-10 Swedish
Cantargia ansöker om pre-IND möte för CAN04 med FDA
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia AB announcing that they have submitted an application for a pre-IND meeting with the FDA regarding their antibody CAN04 and a proposed Phase I combination study in the US. This announcement pertains to regulatory interaction and clinical trial planning for a drug candidate. It is not a full Annual Report (10-K), an Earnings Release (ER), a formal Audit Report (AR), or a general Regulatory Filing (RNS) fallback, as it specifically details an action related to drug development and regulatory submission planning. Since there is no specific category for 'Clinical Trial/Regulatory Submission Update' and the content is highly specific to drug development progress, it best fits under the general 'Regulatory Filings' (RNS) as a significant corporate announcement that doesn't fit the other specialized categories like M&A (TAR) or Financing (CAP). However, given the context of drug development updates, if 'RNS' is used as a general regulatory announcement fallback, it is appropriate. Since the document is a formal press release detailing a regulatory step (pre-IND application), and it is not a report itself (satisfying the 'MENU VS MEAL' rule), RNS is the most suitable general regulatory announcement category.
2019-09-04 Swedish
Cantargia submits request for pre-IND meeting on CAN04 with US FDA
Regulatory Filings Classification · 95% confidence The document is a press release dated September 4, 2019, announcing that Cantargia AB has submitted a request for a pre-IND meeting with the US FDA regarding their drug candidate CAN04. This announcement concerns regulatory interaction and clinical development strategy, but it is not a formal regulatory filing like a 10-K, an earnings release, or a dividend notice. It is a specific update on legal/regulatory progress concerning a drug trial. Among the provided categories, 'Legal Proceedings Report (LTR)' is the closest fit as it covers updates on significant lawsuits or regulatory actions, although this is a proactive regulatory submission rather than a response to an action. However, given the nature of biotech/pharma updates regarding FDA submissions, which are crucial regulatory milestones, and the lack of a specific 'Regulatory Submission Update' category, this falls under general regulatory/legal communication. Since it is a specific announcement about engaging with a regulatory body (FDA) concerning clinical trials, and it doesn't fit the other specific financial or operational categories, it is best classified as a general Regulatory Filing (RNS) as a fallback, or potentially LTR if the FDA interaction is viewed as a regulatory hurdle/proceeding. Given the context of a press release announcing a proactive step towards IND approval, RNS (General regulatory announcements and fallback) is the most appropriate general classification when a specific 'Regulatory Submission' code is absent. The document length (3171 chars) is short, but it contains the full substance of the announcement, not just a pointer to another document, so RPA is not applicable.
2019-09-04 English
Cantargia announce positive preclinical data on CAN04 in bladder cancer
Regulatory Filings Classification · 95% confidence The document is a 'Press release' announcing 'new positive preclinical data' regarding the company's antibody CAN04 in bladder cancer. It details scientific findings, market opportunity, and future development plans. It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT), a formal dividend notice (DIV), or a management remuneration report (DEF 14A). Since it is an announcement of scientific/clinical progress and business development, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for general corporate news releases that don't fit the more specific categories like ER (Earnings Release) or CAP (Financing Update). Given the content is scientific/pipeline news rather than financial results, RNS is the most appropriate general classification.
2019-08-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.